Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Hold” from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned a consensus rating of “Hold” from the thirty research firms that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $33.76.

Several research analysts have weighed in on SRPT shares. Piper Sandler boosted their price target on Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Wall Street Zen downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Wedbush started coverage on Sarepta Therapeutics in a research report on Tuesday, December 9th. They set an “outperform” rating and a $32.00 target price on the stock. Barclays decreased their price target on Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 5th. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a research note on Wednesday.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Inspire Investing LLC acquired a new stake in Sarepta Therapeutics during the first quarter worth about $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Sarepta Therapeutics by 54.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock valued at $29,570,000 after purchasing an additional 164,041 shares in the last quarter. Tempus Wealth Planning LLC grew its holdings in shares of Sarepta Therapeutics by 475.8% during the 2nd quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 17,070 shares during the period. Assenagon Asset Management S.A. increased its position in Sarepta Therapeutics by 21.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company’s stock worth $14,842,000 after purchasing an additional 155,358 shares in the last quarter. Finally, CWM LLC raised its holdings in Sarepta Therapeutics by 4,033.3% in the third quarter. CWM LLC now owns 72,705 shares of the biotechnology company’s stock valued at $1,401,000 after buying an additional 70,946 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Down 6.5%

SRPT opened at $21.31 on Friday. The firm has a market cap of $2.23 billion, a P/E ratio of -7.08, a PEG ratio of 0.50 and a beta of 0.48. The business’s fifty day simple moving average is $20.71 and its 200 day simple moving average is $19.65. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $120.05. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The business’s quarterly revenue was down 14.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.62 earnings per share. As a group, equities research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.